Blog Category

Press Releases

Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd

, , ,

/

19 January 2023

Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed Event

, , ,

/

5 January 2023

DECEMBER 1st, 2022

,

/

1 December 2022

Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19

, , ,

/

3 November 2022

Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones

,

/

1 November 2022

Biophytis announces receipt of Nasdaq Notice

,

/

26 October 2022

Biophytis participates in H.C. Wainwright 24 th Annual Global Investment Conference

,

/

15 September 2022

SEPTEMBRE 13, 2022

, , ,

/

13 September 2022

Top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101)

, , ,

/

7 September 2022

Biophytis to update on the development of Sarconeos (BIO101) in Covid-19 at the 4 th Annual Longevity Therapeutics Summit

,

/

4 July 2022

Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million

,

/

30 June 2022

Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15 th SCWD International Congress

,

/

27 June 2022